Malaria Immunology Lab at ISGlobal
@malaria-immuno.bsky.social
5/ Congratulations to both Marloes and Jeremia on their outstanding work, and thank you to LUMC for such a memorable academic tradition! 👏
November 28, 2025 at 12:27 PM
5/ Congratulations to both Marloes and Jeremia on their outstanding work, and thank you to LUMC for such a memorable academic tradition! 👏
4/ Both of them were under the supervision of Prof. Dr. Maria Yazdanbakhsh. The ceremonies took place at the beautiful Academiegebouw in Leiden, a place that impressed our team, but not as much as the scientific excellence of the candidates! 😊
November 28, 2025 at 12:27 PM
4/ Both of them were under the supervision of Prof. Dr. Maria Yazdanbakhsh. The ceremonies took place at the beautiful Academiegebouw in Leiden, a place that impressed our team, but not as much as the scientific excellence of the candidates! 😊
3/ Carlota Dobaño was part of the opposition committee for Jeremia Pyuza, defending his thesis “The immune divide: factors influencing immune variation and differences in vaccine response.”
November 28, 2025 at 12:27 PM
3/ Carlota Dobaño was part of the opposition committee for Jeremia Pyuza, defending his thesis “The immune divide: factors influencing immune variation and differences in vaccine response.”
2/ @moncunill.bsky.social served as an opponent for the defense of Marloes van Dorst, presenting her thesis “Overlapping patterns and unique differences: A study into immunological variation within and between populations.”
November 28, 2025 at 12:26 PM
2/ @moncunill.bsky.social served as an opponent for the defense of Marloes van Dorst, presenting her thesis “Overlapping patterns and unique differences: A study into immunological variation within and between populations.”
Check out the infographic we prepared and visit the project website to learn more about this exciting work lead by Ron Hokke and his team at LUMC and with collaborations with all the partners you see in the infographic!
➡️ www.wormvacs.org
➡️ www.wormvacs.org
November 27, 2025 at 3:39 PM
Check out the infographic we prepared and visit the project website to learn more about this exciting work lead by Ron Hokke and his team at LUMC and with collaborations with all the partners you see in the infographic!
➡️ www.wormvacs.org
➡️ www.wormvacs.org
8/ Our contribution to WORMVACS2.0 focuses on closing critical knowledge gaps in human immunology to ultimately support the development of vaccines 💉 against two major helminths: Necator americanus and Schistosoma mansoni.
November 27, 2025 at 3:39 PM
8/ Our contribution to WORMVACS2.0 focuses on closing critical knowledge gaps in human immunology to ultimately support the development of vaccines 💉 against two major helminths: Necator americanus and Schistosoma mansoni.
7/ His presentation set the stage for introducing the optimization of a Luminex panel to measure antibody levels and antibody functionality for helminth antigens within the WORMVACS2.0 project.
November 27, 2025 at 3:38 PM
7/ His presentation set the stage for introducing the optimization of a Luminex panel to measure antibody levels and antibody functionality for helminth antigens within the WORMVACS2.0 project.
6/ Alfons Jiménez Morera is a senior technician and one of our Luminex experts 🪄 He delivered a master class on helminths 🪱 that left half of the group with their jaws on the floor because they were not aware of the devastating effects and symptoms these parasites cause.
November 27, 2025 at 3:38 PM
6/ Alfons Jiménez Morera is a senior technician and one of our Luminex experts 🪄 He delivered a master class on helminths 🪱 that left half of the group with their jaws on the floor because they were not aware of the devastating effects and symptoms these parasites cause.
5/ If you are interested in this project, stay tuned for the upcoming paper and feel free to revisit our two previous publications on this topic:
📖 pubmed.ncbi.nlm.nih.gov/33746958/
📖 pubmed.ncbi.nlm.nih.gov/33636218/
📖 pubmed.ncbi.nlm.nih.gov/33746958/
📖 pubmed.ncbi.nlm.nih.gov/33636218/
November 27, 2025 at 3:38 PM
5/ If you are interested in this project, stay tuned for the upcoming paper and feel free to revisit our two previous publications on this topic:
📖 pubmed.ncbi.nlm.nih.gov/33746958/
📖 pubmed.ncbi.nlm.nih.gov/33636218/
📖 pubmed.ncbi.nlm.nih.gov/33746958/
📖 pubmed.ncbi.nlm.nih.gov/33636218/
4/ Some of the main goals of the study are to understand:
👉 How antibodies are transferred from mothers to babies
👉 How different factors, such as maternal HIV infection, affect this transfer
👉 How humoral immunity at birth, along with these factors, shapes malaria exposure during early infancy
👉 How antibodies are transferred from mothers to babies
👉 How different factors, such as maternal HIV infection, affect this transfer
👉 How humoral immunity at birth, along with these factors, shapes malaria exposure during early infancy
November 27, 2025 at 3:36 PM
4/ Some of the main goals of the study are to understand:
👉 How antibodies are transferred from mothers to babies
👉 How different factors, such as maternal HIV infection, affect this transfer
👉 How humoral immunity at birth, along with these factors, shapes malaria exposure during early infancy
👉 How antibodies are transferred from mothers to babies
👉 How different factors, such as maternal HIV infection, affect this transfer
👉 How humoral immunity at birth, along with these factors, shapes malaria exposure during early infancy
3/ The iMIPPAD project focuses on the immunological analysis of serum samples collected from mothers at delivery, their cord blood and their infants. The babies are followed for up to 12 months, with several sampling visits throughout this period.
November 27, 2025 at 3:35 PM
3/ The iMIPPAD project focuses on the immunological analysis of serum samples collected from mothers at delivery, their cord blood and their infants. The babies are followed for up to 12 months, with several sampling visits throughout this period.
2/ Elisa Fuentes Raventós, a PhD student in our lab, walked us through the tremendous work she has done analyzing the newest data from the iMIPPAD project, which will soon see the light in a forthcoming publication!
November 27, 2025 at 3:35 PM
2/ Elisa Fuentes Raventós, a PhD student in our lab, walked us through the tremendous work she has done analyzing the newest data from the iMIPPAD project, which will soon see the light in a forthcoming publication!
9/ It was an inspiring meeting, and truly encouraging to see the passion and dedication of everyone working to improve the lives of people living with Long COVID.
November 25, 2025 at 4:37 PM
9/ It was an inspiring meeting, and truly encouraging to see the passion and dedication of everyone working to improve the lives of people living with Long COVID.
8/ 💻 Methodological challenges: the need for robust study designs that address the lack of a gold standard and the complexity inherent to such a heterogeneous condition.
November 25, 2025 at 4:36 PM
8/ 💻 Methodological challenges: the need for robust study designs that address the lack of a gold standard and the complexity inherent to such a heterogeneous condition.
7/ 🧪 Biomarkers and endotypes: progress toward integrated panels to improve diagnosis, stratification and clinical management.
November 25, 2025 at 4:36 PM
7/ 🧪 Biomarkers and endotypes: progress toward integrated panels to improve diagnosis, stratification and clinical management.
6/ 🦠 Emerging hypotheses: insights on viral persistence, immune and metabolic dysfunction, and potential tissue reservoirs.
November 25, 2025 at 4:36 PM
6/ 🦠 Emerging hypotheses: insights on viral persistence, immune and metabolic dysfunction, and potential tissue reservoirs.
5/ 👶 Pediatric perspective: how Long COVID manifests in children and adolescents, and how this differs from adults.
November 25, 2025 at 4:35 PM
5/ 👶 Pediatric perspective: how Long COVID manifests in children and adolescents, and how this differs from adults.
4/ 🏥 Disease management: current approaches to improving care and emerging evidence on preventive and therapeutic options.
November 25, 2025 at 4:35 PM
4/ 🏥 Disease management: current approaches to improving care and emerging evidence on preventive and therapeutic options.
3/ 🧬 Current state of Long COVID science: advances in identifying patient profiles and the importance of classifying the heterogeneity of the syndrome.
November 25, 2025 at 4:35 PM
3/ 🧬 Current state of Long COVID science: advances in identifying patient profiles and the importance of classifying the heterogeneity of the syndrome.
2/ It was a great opportunity to connect with global experts and deepen our understanding of this complex condition. Throughout the conference, we had the chance to learn about: 👇
November 25, 2025 at 4:35 PM
2/ It was a great opportunity to connect with global experts and deepen our understanding of this complex condition. Throughout the conference, we had the chance to learn about: 👇